Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025, and will present the latest data related to CARVYKTI and other pipelines at the 67th American Society of Hematology Annual Meeting in San Diego from December 6 to 9, 2025 [1] Company Summary - Kingsray Biotechnology's affiliate, Legend Biotech, is listed on the NASDAQ Global Select Market [1] - The presentation at the American Society of Hematology Annual Meeting will focus on CARVYKTI and other pipeline developments [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1] Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025 [1] - The presentation at the American Society of Hematology Annual Meeting will showcase advancements related to CARVYKTI® [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025, and will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1]. Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech, is listed on the NASDAQ Global Select Market [1]. - The 67th American Society of Hematology Annual Meeting will take place in San Diego [1]. - The presentation will include the latest data on CARVYKTI® and other related pipelines [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 關於前瞻性陳述的注意事項 本公告中關於未來預期、計劃和前景的陳述，以及關於非歷史事實事項的任何其他陳述，均構 成1995年《私人證券訴訟改革法案》所指的「前瞻性陳述」。這些陳述包括但不限於：與傳奇 戰略和目標有關的表述，以及傳奇候選產品的潛在優勢。「預期」、「相信」、「繼續」、 「可能」、「估計」、「期望」、「打算」、「可以」、「計劃」、「潛在」、「預測」、 「預計」、「應該」、「目標」、「將」、「會」和類似表達旨在識別前瞻性陳述，但並非所 有前瞻性陳述都包含這些識別詞。儘管並非所有前瞻性表述都包含這些識別詞，但類似表述旨 在識別前瞻性表述。由於各種重要因素的影響，實際結果可能與這些前瞻性陳述所顯示的結果 存在實質性差異。傳奇的預期可能會受到以下因素的影響：新藥開發過程中的不確定性；意外 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown significant market activity, with a recent increase of 3.38% and a trading volume of 170 million yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) reached a new high in both scale and shares since its inception as of October 31 [1] - The ETF has experienced net inflows for 4 out of the last 5 trading days, totaling 18.9 million yuan [1] - The index it tracks, the National Certificate Hong Kong Stock Connect Innovative Drug Index, rose by 3.67%, with notable increases in component stocks such as Senhwa Biosciences (up 10.11%) and Kanglongda (up 8.80%) [1] Group 2: Policy and Industry Insights - The ongoing negotiations for the National Medical Insurance drug list are complemented by a new commercial health insurance innovative drug directory, aimed at providing new payment channels for high-value innovative drugs [1] - The CAR-T cell drug, Rukiyou Lunsai injection from WuXi AppTec, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, with a listed price of 1.29 million yuan per injection [1] - Open Source Securities notes that the current innovative drugs included in both medical insurance and commercial insurance are in the early stages of volume growth, with potential for rapid revenue increases as policies continue to support innovative drugs [2] Group 3: Institutional Investment Trends - According to Guotou Securities, the proportion of all funds heavily invested in Biotech innovative drug companies has increased to 27.53%, reflecting a 2.61 percentage point rise, indicating growing institutional interest in the innovative drug sector [2] - The increasing allocation of funds to the innovative drug sector suggests a strong market recognition of its long-term development potential [2]

Core Insights - The article highlights the success of Carvykti (siltuximab), a CAR-T cell therapy developed by Legend Biotech, which has achieved over $1 billion in sales, marking it as a "blockbuster" drug in the biopharmaceutical industry [3][4]. Sales Performance - Carvykti's sales for Q3 reached $524 million, with cumulative sales for the year amounting to $1.332 billion, including $369 million in Q1 and $439 million in Q2 [3][4]. - The drug was first approved in the U.S. on February 28, 2022, and has since been approved in Japan, the EU, and China, although it has not yet been marketed in China [4]. Market Dynamics - In the Chinese market, there are currently seven CAR-T cell therapies approved, but high prices limit accessibility, with Carvykti priced at $555,300 in the U.S., significantly higher than the domestic CAR-T therapies priced over 1 million [4]. - The global sales of Carvykti are showing a stable growth trend, primarily in the multiple myeloma indication, where it has demonstrated significant efficacy [4][5]. Clinical Data - Recent long-term follow-up data from the CARTITUDE-1 study indicated that 33% of patients with relapsed or refractory multiple myeloma experienced no disease progression for five years after a single infusion of Carvykti, marking a significant advancement in treatment outcomes [5]. Financial Outlook - Legend Biotech is on track to turn a profit by 2026, following a net loss of approximately $101 million in Q1 2025, driven by the increasing sales of Carvykti [6][8].

Core Viewpoint - Kingsoft Biotech (1548.HK) has seen a significant stock price increase of 4.71% to HKD 16.67, with a year-to-date gain of nearly 70%, outperforming the market index which has risen approximately 30% during the same period [1] Group 1: Company Performance - Kingsoft Biotech's stock price has increased by 4.71% to HKD 16.67 during intraday trading [1] - The company has achieved a year-to-date stock price increase of nearly 70% [1] - The performance of Kingsoft Biotech has outpaced the Hang Seng Index, which has risen about 30% in the same timeframe [1] Group 2: Business Developments - Kingsoft Biotech announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on October 14, 2025 [1] - The report indicated that CARVYKTI® generated trade sales net revenue of approximately USD 524 million for the quarter ending September 30, 2025, under a collaboration and licensing agreement with Janssen Biotech, Inc. established on December 21, 2017 [1]

Group 1 - Kingsray Biotechnology (01548) saw a stock increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD [1] - On October 14, Kingsray Biotechnology announced that, according to the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate net trade sales of approximately 524 million USD for the quarter ending September 30, 2025 [1]

Group 1 - Kingsray Biotechnology (01548) saw a stock increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD [1] - On October 14, Kingsray Biotechnology announced that, according to the collaboration and licensing agreement with Janssen Biotech, Inc. established on December 21, 2017, CARVYKTI is projected to generate net trade sales of approximately 524 million USD for the quarter ending September 30, 2025 [1]

Core Viewpoint - Kingsray Biotechnology (01548) has seen a stock price increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD, following the announcement of projected trade sales from its collaboration with Janssen Biotech, Inc. [1] Group 1 - Kingsray Biotechnology announced that CARVYKTI is expected to generate trade sales net revenue of approximately 524 million USD for the quarter ending September 30, 2025, as per the collaboration and licensing agreement established with Janssen on December 21, 2017 [1]